Cargando…
Cardiovascular Toxicity During Advanced Prostate Cancer Treatment: Minding the Heart
[Figure: see text]
Autores principales: | Dorff, Tanya, Rhee, June-Wha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635875/ https://www.ncbi.nlm.nih.gov/pubmed/37969657 http://dx.doi.org/10.1016/j.jaccao.2023.07.005 |
Ejemplares similares
-
The new era of prostate-specific membrane antigen-directed immunotherapies
and beyond in advanced prostate cancer: a review
por: Martin, Felicity C., et al.
Publicado: (2023) -
Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer
por: Dorff, Tanya B., et al.
Publicado: (2022) -
Bone-targeted therapies to reduce skeletal morbidity in prostate cancer
por: Dorff, Tanya B, et al.
Publicado: (2018) -
Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
por: Yu, Steven S, et al.
Publicado: (2016) -
Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients
por: Lyou, Yung, et al.
Publicado: (2021)